Fibrinogen is a co-antioxidant that supplements the vitamin E analog trolox in a model system.
OBJECTIVE
It appears that the atherosclerotic plaque is a prooxidant environment where some molecules that are normally antioxidants, including vitamins C and E, may act as prooxidants that contribute to atherosclerosis by oxidizing LDL. Some molecules can act as co-antioxidants to eliminate this prooxidant effect by recycling or other mechanisms of supplementation. Fibrinogen and other acute phase proteins found in the plaque are antioxidants. We hypothesized that fibrinogen can act as a co-antioxidant to supplement vitamin E thereby eliminating its oxidative effect under prooxidant conditions. We tested a model system for this hypothesis using the vitamin E analogue Trolox in a cell free system.


METHODS
LDL was oxidized using 5 umol/l copper. Antioxidant conditions were achieved by adding the antioxidants immediately with LDL, while prooxidant conditions were created by adding antioxidants after a 40 min delay. Oxidation was monitored as the lag phase at 234 nm.


RESULTS
Under antioxidant conditions, the protective effect of fibrinogen and Trolox combined together were about equal to the sum of the anitioxidant effects of each alone (additive), while under prooxidant conditions the combined protection was 54-200% greater (synergistic). These effects were different than those of vitamin C with Trolox in that under antioxidant conditions fibrinogen and Trolox were additive while vitamin C and Trolox showed strong synergistic effects, and in that unlike vitamin C and Trolox fibrinogen showed no prooxidant tendencies under prooxidant reaction conditions.


CONCLUSIONS
The data indicated that fibrinogen did act as a co-antioxidant to supplement Trolox and eliminate its prooxidant effect, most probably, by directly quenching the phenoxyl radical, because unlike vitamin C, fibrinogen did not appear to recycle vitamin E. But fibrinogen may act as a universal antioxidant, since unlike Trolox and vitamin C, it showed little tendency toward becoming a prooxidant.
Abudu
Ntei
N
Department of Pathology and Laboratory Medicine, University of Louisville, KY, 40292, USA.
Miller
James J
JJ
Levinson
Stanley S
SS
D000975:Antioxidants / Q000494:pharmacology*; D001205:Ascorbic Acid / Q000494:pharmacology; D002839:Chromans / Q000494:pharmacology*; D019587:Dietary Supplements; D004357:Drug Synergism; D005340:Fibrinogen / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008077:Lipoproteins, LDL / Q000737:chemistry / Q000378:metabolism*; D008954:Models, Biological; D016877:Oxidants / Q000494:pharmacology*; D010084:Oxidation-Reduction
D000975:Antioxidants; D002839:Chromans; D008077:Lipoproteins, LDL; D016877:Oxidants; D005340:Fibrinogen; D001205:Ascorbic Acid; C010643:6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid